Trials / Completed
CompletedNCT02804763
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 182 (actual)
- Sponsor
- UCB Biopharma S.P.R.L. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose is to evaluate the efficacy and safety of three different doses of Dapirolizumab Pegol (DZP) versus placebo in adult subjects with moderately to severely active systemic Lupus Erythematosus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Solution for infusion, 0,9% saline |
| DRUG | Dapirolizumab pegol (DZP) | Solution for infusion |
Timeline
- Start date
- 2016-06-02
- Primary completion
- 2018-05-31
- Completion
- 2018-11-19
- First posted
- 2016-06-17
- Last updated
- 2021-06-30
- Results posted
- 2021-06-30
Locations
71 sites across 13 countries: United States, Bulgaria, Chile, Colombia, Germany, Hungary, Mexico, Peru, Poland, Romania, Russia, Spain, Ukraine
Source: ClinicalTrials.gov record NCT02804763. Inclusion in this directory is not an endorsement.